Keybanc analyst Scott Schoenhaus maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $23 to $20.

JMP Securities analyst Constantine Davides reiterates Certara (NASDAQ:CERT) with a Market Perform.

Certara, excluding Chemaxon, is reiterating 2024 revenue, adjusted EBITDA margin, and adjusted diluted earnings per share guidance consistent with the May 7th earnings call. Following transaction close, Certara will update its 2024 guidance to include contribution from Chemaxon and expects to maintain its 2024 adjusted EBITDA margin guidance of 31-33%. 

The transaction is expected to close in the second half of 2024, subject to regulatory approval and other customary closing conditions. In 2024, Chemaxon is expected to generate software revenue greater than $20 million. Chemaxon has a revenue growth profile comparable to Certara's software business and is expected to reach an adjusted EBITDA margin near Certara's corporate average by the end of 2025.

Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and lowers the price target from $18 to $16.

Certara (NASDAQ:CERT) reported quarterly earnings of $0.10 per share which met the analyst consensus estimate. The company reported quarterly sales of $96.654 million which beat the analyst consensus estimate of $93.637 million by 3.22 percent. This is a 7.04 percent increase over sales of $90.301 million the same period last year.

RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024. Third Quarter Highlights: Revenue was $94.8 million, compared to $85.6 million in the third quarter of 2023, representing growth of 11%. Software revenue was $35.9 million, compared to $31.3 million in the third quarter of 2023, representing growth of 15%.Services revenue was $58.9 million, compared to $54.2 million in the third quarter of 2023, representing growth of 9%. Net loss was $1.4 million, compared to a net loss of $49.0 million in the third quarter of 2023. The $47.6 millio

RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment Conference. Company management will present at 10:00AM CT on Thursday, November 21st, 2024. A live webcast of the event will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. About CertaraCertara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutic

RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. "We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara's Board," said William F. Feehery, PhD, CEO of Certara. "John's expertise in artificial intelligence, data science, and life science will provide immense value. We will draw on that expertise as we continue to develop and integrate transformational software and services that accelerate new medicines and increase the productivity of pharma R&

ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe

RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using

RADNOR, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced it has completed the acquisition of Chemaxon. Chemaxon develops leading scientific informatics software products used by the life sciences industry for in-silico research. Certara develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties of large and small molecules. "Combining Chemaxon's expertise with Certara's biosimulation capabilities provides life sciences companies with unique solutions to enhance productivity and increase their scientific innovation success rates," said Willi

RADNOR, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announces the celebration of the 25th anniversary of the Simcyp® Consortium. The Simcyp Consortium has become a global authority on mechanistic physiologically-based pharmacokinetic (PBPK) modeling and simulation. With members from 35 leading biopharmaceutical companies, the Simcyp® Consortium was created to guide the development of best practices, identify the most critical use areas, and fill the scientific gaps that were needed for studying drug handling by the body in computer-generated, virtual patients and beyond the limited framework of clinical tri

RADNOR, Pa., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001. IGI's drug candidate is a trispecific T-cell engager (TCE) being studied as a potential cancer treatment. Preclinical research and biosimulation findings were recently published in Nature Cancer. This publication highlighted ISB 2001's therapeutic potential for relapsed/refractory multiple myeloma patients. Difficulties translating data from animals to patients traditionally limit first-in-human (FIH) dose sele

RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare ConferenceDate and Time: Wednesday, September 4 at 4:05 p.m. ET Baird Global Healthcare ConferenceDate and Time: Wednesday, September 11 at 10:15 a.m. ET Live webcasts for each of the conferences will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. About CertaraCertara accelerates medicines using biosimulation software, techno

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the pharmaceutical industry's gold standard in pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. The Phoenix Platform is used by more than 75 of the top 100 pharmaceutical companies worldwide. Eleven regulatory agencies, including the U.S. FDA, Japan PMDA, and China NMPA, rely on Phoenix to evaluate life-saving drug candidates. Version 8.5 is the latest release from Certara's Phoenix Platform, available as a hosted solution for maximum performance and lower tot

UBS upgraded Certara from Neutral to Buy and set a new price target of $16.00

KeyBanc Capital Markets upgraded Certara from Sector Weight to Overweight and set a new price target of $23.00

JMP Securities initiated coverage of Certara with a rating of Mkt Perform

Leerink Partners initiated coverage of Certara with a rating of Market Perform and set a new price target of $19.00

UBS initiated coverage of Certara with a rating of Neutral and set a new price target of $17.00

KeyBanc Capital Markets initiated coverage of Certara with a rating of Sector Weight

Jefferies downgraded Certara from Buy to Hold and set a new price target of $17.00 from $24.50 previously

William Blair downgraded Certara from Outperform to Mkt Perform

Stephens initiated coverage of Certara with a rating of Overweight and set a new price target of $28.00

Barclays downgraded Certara from Overweight to Equal Weight and set a new price target of $25.00

10-Q - Certara, Inc. (0001827090) (Filer)

8-K - Certara, Inc. (0001827090) (Filer)

8-K - Certara, Inc. (0001827090) (Filer)

144 - Certara, Inc. (0001827090) (Subject)

10-Q - Certara, Inc. (0001827090) (Filer)

8-K - Certara, Inc. (0001827090) (Filer)

8-K - Certara, Inc. (0001827090) (Filer)

8-K - Certara, Inc. (0001827090) (Filer)

8-K - Certara, Inc. (0001827090) (Filer)

8-K - Certara, Inc. (0001827090) (Filer)

4 - Certara, Inc. (0001827090) (Issuer)

3 - Certara, Inc. (0001827090) (Issuer)

4 - Certara, Inc. (0001827090) (Issuer)

4 - Certara, Inc. (0001827090) (Issuer)

4 - Certara, Inc. (0001827090) (Issuer)

4 - Certara, Inc. (0001827090) (Issuer)

4 - Certara, Inc. (0001827090) (Issuer)

4 - Certara, Inc. (0001827090) (Issuer)

3 - Certara, Inc. (0001827090) (Issuer)

3 - Certara, Inc. (0001827090) (Issuer)

RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. "We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara's Board," said William F. Feehery, PhD, CEO of Certara. "John's expertise in artificial intelligence, data science, and life science will provide immense value. We will draw on that expertise as we continue to develop and integrate transformational software and services that accelerate new medicines and increase the productivity of pharma R&

ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe

RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel. "Rona and Daniel are leaders in their fields. They have proven track records of growing teams and building high-performing businesses," said William F. Feehery Ph.D., CEO, Certara. "I'm confident they will further Certara's mission of accelerating medicines to patients through the delivery of solutions that improve the entire drug research and development process." Ms. Anhalt will drive Certara's human capital management strategy. She will lead the company's global

PRINCETON, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective July 21, 2022. Her appointment brings the company's board of directors to eleven members. "We are excited to welcome an accomplished business leader with a proven track record of success join Certara's Board," said William F. Feehery, PhD, CEO of Certara. "Rose's experience in executive leadership and expertise in commercialization will provide immense value as the Company grows its impact on the biopharmaceutical industry worldwide." Ms. Crane has more than 35 years of experience in the ph

PRINCETON, N.J., July 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced the appointment of Eran Broshy to its Board of Directors, effective July 11, 2022. His appointment brings the company's board of directors to ten members. "Eran has a proven track record taking high-growth healthcare businesses to the next level and delivering superior results," said William Feehery, Ph.D., CEO of Certara. "Certara is excited to have someone of his caliber and experience join the board. I look forward to Eran's contribution in guiding us as we grow our impact by informing critical decisions in drug development with biosimulation, technology and

PRINCETON, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced that James E. Cashman III, a current Board member, will be appointed Chairman of the Board of Directors, effective as of December 1, 2021. Jim succeeds Sherilyn McCoy, who is stepping down from the Board to focus on other professional commitments. "It has been a privilege to serve as Chairman of Certara's Board of Directors, and I am proud of the Company's strong performance and accomplishments," said Ms. McCoy. "Certara is well-positioned for continued success with an outstanding leadership team." "On behalf of the Board, I would like to thank Sheri for a

PRINCETON, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced the appointment of Patrick F. Smith, Pharm.D. as president of Integrated Drug Development (IDD), reporting to CEO William F. Feehery. Dr. Smith will lead the Company's global drug development services team, which creates value for clients across the entire drug development life cycle using biosimulation and quantitative approaches. Dr. Smith succeeds Craig R. Rayner, Pharm.D., who has served as president of IDD since 2019 and will be appointed to the role of Certara distinguished scientist, leading key strategic client engagements and scientific innovation. "I

PRINCETON, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in biosimulation, today announced the appointment of Drayton T. Virkler to the newly created position of Chief Commercial Officer. In this role, Mr. Virkler will drive the Company's global commercial strategy and execution and expand the business development team. "I am pleased to welcome Drayton as our new Chief Commercial Officer," said William F. Feehery, Ph.D., CEO of Certara. "His role will be vital to advancing our business growth strategy of global expansion and deepening our partnerships with biopharmaceutical clients. Drayton's extensive leadership experience and commercial knowledge w

PRINCETON, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced the appointments of Nancy Killefer and Cynthia Collins to its board of directors, effective August 1, 2021. The two additional appointments increase the company's board of directors to eleven members. "It's truly a pleasure to welcome Nancy and Cynthia to the board of directors," said Sheri McCoy, board chairman. "Their wealth of knowledge and extensive corporate board and leadership experience will be essential to us and no doubt strengthen our guidance of Certara." Ms. Killefer brings more than three decades of executive experience across the pharmaceutical, healthcare and

PRINCETON, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Certara®, a global leader in biosimulation, today announced that it has appointed Nicolette D. Sherman to the position of Chief Human Resources Officer (CHRO). Sherman joins Certara with extensive experience in the biopharmaceutical industry, leading HR strategy and implementing programs to drive business impact. "We are pleased to have Nicolette join Certara as we continue to grow our high-performing team and capabilities worldwide," said William F. Feehery, chief executive officer. "She has a proven track record of achieving organizational results through advancing corporate values and building competencies. We look forward to her contr